Table 1.

Patient and Tumor Characteristics

Regimen	RT with Cisplatin (n=18)		RT with Cetuximab (n=29)		p-value
Characteristic	No.	%	No.	%
Age (years) Median	55		62		0.015
Range	35–78		46–86
Sex					0.32
Male	15	83.3	19	65.5
Female	3	16.7	10	34.5
Race					0.99
Caucasian	14	77.8	21	72.4
African American	3	16.7	6	20.7
Native American	1	5.6	2	6.9
Smoking History					0.94
Yes	14	77.8	26	89.7
No	4	22.2	3	10.3
Insurance					0.076
Private	5	27.8	4	13.8
Medicare	3	16.7	15	51.7
Medicaid	9	50.0	9	31.0
None	1	5.6	1	3.4
ECOG performance status					0.042
0	11	61.1	8	27.6
1	4	22.2	13	44.8
2	3	16.7	6	20.7
3	0	0.0	2	6.9
ACE Comorbidity Index					0.083
0 (none)	5	27.8	5	17.2
1 (mild)	7	38.9	8	27.6
2 (moderate)	4	22.2	5	17.2
3 (severe)	2	11.1	11	37.9
Primary Site					0.29
Oropharynx	10	55.6	13	44.8
Oral Cavity	0	0.0	3	10.3
Larynx	7	38.9	7	24.1
Level II/III Neck Mass (Unknown Primary)	1	5.6	2	6.9
Hypopharynx	0	0.0	4	13.8
T Classification					0.58
T1	0	0.0	1	3.4
T2	0	0.0	3	10.3
T3	8	44.4	10	34.5
T4	9	50.0	13	44.8
Tx	1	5.6	2	6.9
N Classification					0.66
N0 & N1	6	33.3	12	41.4
N2a-c	11	61.1	15	51.7
N3	1	5.6	2	6.9
Overall Stage					0.55
III	3	16.7	7	24.1
IVa/IVb	15	83.3	22	75.9
HPV-Related					0.99
Oropharynx	7		7
Level II/III neck mass (Unknown primary)	1		1
Hypopharynx	0		1